$TOVX
Theriva Biologics, Inc.

2015 Q2 Form 10-Q Financial Statement

#000114420415047629 Filed on August 10, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2014 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.220M $1.810M
YoY Change 22.65% 43.65%
% of Gross Profit
Research & Development $7.508M $2.837M
YoY Change 164.65% 135.83%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $9.730M $4.651M
YoY Change 109.2% 88.99%
Operating Profit -$9.730M -$4.651M
YoY Change 109.2%
Interest Expense $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net -$3.893M $95.00K
YoY Change -4197.89% -363.89%
Pretax Income -$9.730M -$4.651M
YoY Change 109.2% 88.99%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.62M -$4.556M
YoY Change 199.01% 82.46%
Net Earnings / Revenue
Basic Earnings Per Share -$0.19
Diluted Earnings Per Share -$0.19 -$2.731M
COMMON SHARES
Basic Shares Outstanding 72.74M shares 58.45M shares
Diluted Shares Outstanding 72.74M shares

Balance Sheet

Concept 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.760M $7.840M
YoY Change -39.29% 13.95%
Cash & Equivalents $4.757M $7.843M
Short-Term Investments
Other Short-Term Assets $6.955M $1.389M
YoY Change 400.72% -26.12%
Inventory
Prepaid Expenses $315.0K $52.00K
Receivables
Other Receivables
Total Short-Term Assets $11.71M $9.232M
YoY Change 26.84% -2.38%
LONG-TERM ASSETS
Property, Plant & Equipment $110.0K $51.00K
YoY Change 115.69% -67.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.00K $10.00K
YoY Change 100.0% -50.0%
Total Long-Term Assets $130.0K $57.00K
YoY Change 128.07% -66.47%
TOTAL ASSETS
Total Short-Term Assets $11.71M $9.232M
Total Long-Term Assets $130.0K $57.00K
Total Assets $11.84M $9.289M
YoY Change 27.46% -3.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.690M $1.079M
YoY Change 705.38% 406.57%
Accrued Expenses $2.010M $153.0K
YoY Change 1213.73% 856.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.50M $1.232M
YoY Change 1969.81% 437.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $25.50M $1.232M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $25.50M $1.230M
YoY Change 1973.17% 437.12%
SHAREHOLDERS EQUITY
Retained Earnings -$89.65M
YoY Change 21.7%
Common Stock $97.71M
YoY Change 17.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$13.66M $8.057M
YoY Change
Total Liabilities & Shareholders Equity $11.84M $9.289M
YoY Change 27.46% -3.54%

Cashflow Statement

Concept 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$13.62M -$4.556M
YoY Change 199.01% 82.46%
Depreciation, Depletion And Amortization $10.00K $10.00K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$7.250M -$3.300M
YoY Change 119.7% 101.22%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K -$20.00K
YoY Change 100.0% 100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$40.00K -$20.00K
YoY Change 100.0% 100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -7.250M -3.300M
Cash From Investing Activities -40.00K -20.00K
Cash From Financing Activities 0.000 0.000
Net Change In Cash -7.290M -3.320M
YoY Change 119.58% 101.21%
FREE CASH FLOW
Cash From Operating Activities -$7.250M -$3.300M
Capital Expenditures -$40.00K -$20.00K
Free Cash Flow -$7.210M -$3.280M
YoY Change 119.82% 101.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
8047000 USD
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.14
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.36
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58348153 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
72674650 shares
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4651000 USD
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58453528 shares
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
72736829 shares
CY2014Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2015Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3895000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-13623000 USD
CY2014Q4 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
525000 USD
us-gaap Net Income Loss
NetIncomeLoss
-25981000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-61000 USD
syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
4000 USD
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
58000 USD
CY2014Q4 syn Accrued Vendor Payments
AccruedVendorPayments
176000 USD
CY2014Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 USD
syn Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
12000 USD
CY2015Q2 us-gaap Profit Loss
ProfitLoss
-13623000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
937000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-144000 USD
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2222000 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2837000 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7508000 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
4651000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8394000 USD
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1814000 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
9730000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9730000 USD
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
95000 USD
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3893000 USD
CY2014Q2 us-gaap Profit Loss
ProfitLoss
-4556000 USD
CY2015Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-4556000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-202000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1000 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-6782000 USD
CY2014Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.08
CY2015Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.19
us-gaap Share Based Compensation
ShareBasedCompensation
1217000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1413000 USD
us-gaap Depreciation
Depreciation
7000 USD
us-gaap Depreciation
Depreciation
19000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5407000 USD
syn Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
2000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7690000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
317000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6765000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12708000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
61000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21000 USD
syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
1000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4000 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-12768000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14625000 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7843000 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
0 USD
syn Stock Issued For Milestone Payments
StockIssuedForMilestonePayments
-1350000 USD
syn Stock Issued For Milestone Payments
StockIssuedForMilestonePayments
0 USD
CY2015Q2 syn Prepaid Expenses Research And Development
PrepaidExpensesResearchAndDevelopment
1049000 USD
CY2014Q4 syn Prepaid Expenses Research And Development
PrepaidExpensesResearchAndDevelopment
1067000 USD
CY2015Q2 us-gaap Prepaid Insurance
PrepaidInsurance
133000 USD
CY2014Q4 us-gaap Prepaid Insurance
PrepaidInsurance
228000 USD
CY2015Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
315000 USD
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
253000 USD
CY2015Q2 us-gaap Other Assets Current
OtherAssetsCurrent
6955000 USD
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1548000 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
39000 USD
CY2015Q2 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
105000 USD
CY2014Q4 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
247000 USD
CY2015Q2 syn Accrued Vendor Payments
AccruedVendorPayments
470000 USD
CY2015Q2 syn Accrued Milestone Payable
AccruedMilestonePayable
0 USD
CY2014Q4 syn Accrued Milestone Payable
AccruedMilestonePayable
350000 USD
CY2015Q2 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
1040000 USD
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
7029808 shares
CY2014 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
232619 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
454896 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.75
CY2014 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
1.47
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
1.88
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0 shares
syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
61207 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
3.30
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
Synthetic Biologics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0000894158
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
104000 USD
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Trading Symbol
TradingSymbol
SYN
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
88515086 shares
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73260787 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73179305 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72594626 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72513144 shares
CY2015Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
3600000 USD
CY2014Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
13600000 USD
CY2015Q2 syn Prepaid Clinical Research Organizations
PrepaidClinicalResearchOrganizations
5458000 USD
CY2014Q4 syn Prepaid Clinical Research Organizations
PrepaidClinicalResearchOrganizations
0 USD
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
165000 USD
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2015Q2 syn Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod
0 pure
CY2014Q2 syn Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod
0 pure
syn Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod
0 pure
syn Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod
0 pure
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5300000 USD
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1632501 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7974794 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7913587 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.80
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.79
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.99
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
95000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
95000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-732000 USD

Files In Submission

Name View Source Status
0001144204-15-047629-index-headers.html Edgar Link pending
0001144204-15-047629-index.html Edgar Link pending
0001144204-15-047629.txt Edgar Link pending
0001144204-15-047629-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_001.gif Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syn-20150630.xml Edgar Link completed
syn-20150630.xsd Edgar Link pending
syn-20150630_cal.xml Edgar Link unprocessable
syn-20150630_def.xml Edgar Link unprocessable
syn-20150630_lab.xml Edgar Link unprocessable
syn-20150630_pre.xml Edgar Link unprocessable
v416584_10q.htm Edgar Link pending
v416584_ex31-1.htm Edgar Link pending
v416584_ex31-2.htm Edgar Link pending
v416584_ex32-1.htm Edgar Link pending
v416584_ex32-2.htm Edgar Link pending